Back to Agenda
Session 2 - Part 2: Evolving Expectations for Benefit-Risk
Session Chair(s)
Rebecca Noel, DrPH, MPH
Executive Director, Benefit-Risk Assessment
Eli Lilly, United States
In this session, global regulatory and industry representatives will continue to discuss updates on the key benefit-risk initiatives. Participants will have the opportunity to pose questions to the presenters in a panel forum in this session.
Speaker(s)
CIRS Initiative
Lawrence Liberti, PHD, RAC
The Kim Center/ USC DRQS, United States
Director, D.K. Kim International Center for Regulatory Science
FDA Perspective
Andrea Tan
FDA, United States
Operations Research Analyst, OSP, CDER
Panelists
Hans-Georg Eichler, MD, MSC
Austrian Association of Social Security Bodies, Austria
Consulting Physician
Juhaeri Juhaeri, PHD
Sanofi, United States
Vice President and Global Head, Epidemiology and Benefit-Risk Evaluation
Robyn R. Lim, PHD
Health Canada, Canada
Senior Science Advisor, Health Products and Food Branch
Lawrence Liberti, PHD, RAC
The Kim Center/ USC DRQS, United States
Director, D.K. Kim International Center for Regulatory Science
Andrea Tan
FDA, United States
Operations Research Analyst, OSP, CDER
Have an account?